These data demonstrate that especially MS-OCR patients, but not RA-MTX patients, display a strong CD8+ T cell recall response following the first vaccination, while in HCs this recall response is more pronounced following the second vaccination. This evidence concerns the gene CD8A and myeloid sarcoma.